Health condition
Cardiac amyloidosis deep dive
Cardiac amyloidosis is infiltration of the heart muscle by misfolded protein, either transthyretin (ATTR) or light chains (AL); once considered untreatable, both forms now have effective therapies, making early diagnosis vital.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key points
What matters most, at a glance.
The essentials in plain English - symptoms, when to seek help, who to see and what treatment looks like.
-
Suspect it with thickened heart walls plus carpal tunnel syndrome, spinal stenosis, low-flow aortic stenosis or unexplained heart failure in later life
-
DPD bone scintigraphy plus blood and urine light-chain tests can confirm ATTR amyloidosis without biopsy
-
AL amyloidosis is a haematological emergency treated with chemotherapy-based regimens
-
ATTR amyloidosis is treated with the stabiliser tafamidis and, in hereditary forms, gene-silencing therapies
-
Genetic testing distinguishes hereditary ATTR from the commoner wild-type form of older age
Understanding it
About Cardiac amyloidosis deep dive, and what to do next.
Amyloid deposits stiffen and thicken the heart, producing heart failure with a characteristic imaging appearance. ATTR amyloidosis, particularly the wild-type form in older men, is far more common than once believed and frequently masquerades as ordinary heart failure or aortic stenosis.
The diagnostic pathway is now well defined - echocardiography and cardiac MRI raise suspicion, DPD scintigraphy and light-chain testing classify the type, and the National Amyloidosis Centre coordinates confirmation. Because tafamidis and newer agents work best before advanced damage, speed of diagnosis directly affects outcome. Most people start with their GP, who can refer to a consultant cardiologist, with complex cases managed alongside the National Amyloidosis Centre. In many parts of the UK, routine NHS referrals for this kind of problem currently take 20-45+ weeks, whereas an initial private consultation is typically available within around two weeks.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any emergency symptoms described above.
Frequently asked
Common questions about Cardiac amyloidosis deep dive.
Quick, plain-English answers to what people ask us most.
-
What is cardiac amyloidosis?
Cardiac amyloidosis is a condition where abnormal protein deposits (amyloid) build up in the heart muscle, making it stiff and less able to relax and fill with blood properly. This leads to a form of heart failure that can be under-recognised because its symptoms overlap with more common heart conditions. It is increasingly diagnosed thanks to improved imaging and blood tests.
-
What causes cardiac amyloidosis?
The two main types are AL amyloidosis, caused by an abnormal plasma cell disorder producing misfolded light-chain proteins, and ATTR amyloidosis, caused by an unstable transthyretin protein that can be inherited (hereditary ATTR) or occur with ageing (wild-type ATTR). Identifying the specific type is essential because treatments differ substantially between them.
-
What are the symptoms?
Common symptoms include breathlessness, fatigue, swelling in the legs, and sometimes irregular heartbeats or fainting. Clues that suggest amyloidosis rather than more common heart failure include unexplained carpal tunnel syndrome, thickened heart walls without high blood pressure, or low blood pressure with heart failure symptoms. Symptoms often develop gradually and can be mistaken for normal ageing.
-
Is cardiac amyloidosis hereditary?
Hereditary ATTR amyloidosis is caused by an inherited gene mutation and can run in families, while wild-type ATTR amyloidosis and AL amyloidosis are not typically inherited. Genetic testing can clarify which type is present and whether relatives should be assessed. This distinction significantly affects family counselling and management.
-
How is cardiac amyloidosis treated?
AL amyloidosis is usually treated with chemotherapy-type regimens targeting the underlying plasma cell disorder, while ATTR amyloidosis can be treated with specific stabiliser or gene-silencing medications that slow disease progression. Heart failure symptoms are also managed with tailored medications, since some standard heart failure drugs are used cautiously in amyloidosis. Treatment plans require specialist cardiology and haematology input.
-
Cardiac amyloidosis versus other causes of heart failure — what's the difference?
Unlike heart failure from coronary artery disease or high blood pressure, amyloidosis causes stiffening from abnormal protein infiltration rather than muscle damage or pressure overload, and it needs disease-specific treatment rather than standard heart failure therapy alone. Specific imaging findings and blood/urine tests help distinguish it. Recognising amyloidosis changes the treatment approach significantly.
-
When should I see a specialist about possible cardiac amyloidosis?
Seek cardiology assessment if you have unexplained heart failure symptoms combined with clues such as carpal tunnel syndrome, thickened heart walls, or a family history of the condition. NHS cardiology waits can extend to many weeks; a private cardiology consultation is typically available within about 2 weeks for prompt specialist assessment.